OSE Immunotherapeutics' Tedopi Combination Meets Primary Endpoint In NSCLC Trial
(RTTNews) - OSE Immunotherapeutics SA (OSE), a clinical-stage biotech company, announced topline results from the Combi-TED academic Phase 2 international clinical trial of Tedopi sponsored by FoRT and evaluating Tedopi (OSE2101), in combination with either chemotherapy or anti-P
